Honokiol

Phase 1Small molecule

TThe Methodist Hospital Research Institute

Honokiol is one of 22 small molecule programs targeting Carcinoma, Non-Small-Cell Lung. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Carcinoma, Non-Small-Cell LungRecruiting

Carcinoma, Non-Small-Cell LungPhase 1

Recruiting

Competition

Competitive Landscape

24 competitors in Carcinoma, Non-Small-Cell Lung

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

17 2

Imfinzi

AstraZeneca

Phase 3

7 3

Paraplatin

AAvyxa

Phase 3

18 4

Taxol

Teva

Phase 3

5 5

Tagrisso

AstraZeneca

Phase 3

4 6

Alimta

SShawn Eagle

Phase 3

13 7

Rozlytrek

Roche

Phase 3

1 8

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

9 9

Beyfortus

BeiGene

Phase 2

2 10

Direct Anticoagulant

Bayer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06566443

Clinical

Trials by Indication[1]

Carcinoma, Non-Small-Cell Lung1 trial

Phase I Trial Evaluating the Safety of the Dietary Supplement Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer

Recruiting·TThe Methodist Hospital Research Institute·Phase 1·NCT06566443·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Honokiol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Honokiol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Honokiol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Methodist Hospital Research Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: TThe Methodist Hospital Research Institute

Honokiol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Carcinoma, Non-Small-Cell Lung1 trial

References

Drug Info

Quick Facts

Related News